{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:52:01Z","timestamp":1782305521122,"version":"3.54.5"},"reference-count":29,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Monomodal systemic glucocorticoids remain the mainstay of treatment for bullous pemphigoid (BP). In this retrospective, single-arm study, we evaluated the feasibility (efficacy and tolerability) of the combination of methylprednisolone and low-dose (up to 12.5 mg\/week) methotrexate (MP + MTX) for BP. At week 12, 53\/55 (96.4%) patients initiated on MP + MTX during a five-year period (potential follow up time: \u22654 years) remained on treatment. At this time-point, BP remission was achieved in all compliant patients (including n = 24 cases of dipeptidyl peptidase-4 inhibitors-associated BP; 12-week remission rate: 100% [95% CI: 91.9\u2013100.0%]; mean time to remission: 29.5 days, SEM: 2.3 days) at a mean cumulative MP dose to disease control of 678.4 mg (SEM = 49.4 mg). Eight patients relapsed during follow up (10.81 [95% CI: 5.16\u201321.72] relapses\/100 person years, py), and seven manifested a severe adverse event (6.80 [95% CI: 3.00\u201314.28] severe adverse events\/100 py); however, 73.4% (\u00b17.9%) had suffered neither a relapse nor a SAE at the three-years follow up. Continuing low dose MP intake (\u22648 mg\/day) beyond week 12 in combination with MTX minimized the risk of a feasibility limiting event (p = 0.013). Conclusively, the combination of methylprednisolone with methotrexate is a promising, safe, and efficient modality for BP patients, which enables rapid glucocorticoid tapering.<\/jats:p>","DOI":"10.3390\/jcm11113193","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:05:02Z","timestamp":1654167902000},"page":"3193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid\u2014A Single Center Retrospective Analysis"],"prefix":"10.3390","volume":"11","author":[{"given":"Agoritsa","family":"Gravani","sequence":"first","affiliation":[{"name":"Department of Dermatology, University General Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-1304","authenticated-orcid":false,"given":"Georgios","family":"Gaitanis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University General Hospital of Ioannina, 45500 Ioannina, Greece"},{"name":"Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Spyridonos","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Alexis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University General Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-8983","authenticated-orcid":false,"given":"Stelios","family":"Tigas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-8314","authenticated-orcid":false,"given":"Ioannis D.","family":"Bassukas","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case-Control Study","volume":"131","author":"Joly","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of Bullous Pemphigoid: The European Dermatology Forum Consensus in Collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/abd1806-4841.2019940207","article-title":"Consensus on the Treatment of Autoimmune Bullous Dermatoses: Bullous Pemphigoid, Mucous Membrane Pemphigoid and Epidermolysis Bullosa Acquisita\u2014Brazilian Society of Dermatology","volume":"94","author":"Santi","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese Guidelines for the Management of Pemphigoid (Including Epidermolysis Bullosa Acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_5","first-page":"516","article-title":"S2k Guidelines for the Treatment of Pemphigus Vulgaris\/Foliaceus and Bullous Pemphigoid: 2019 Update","volume":"18","author":"Schmidt","year":"2020","journal-title":"JDDG J. Ger. Soc. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(14)61347-7","article-title":"The Burden of Disease in Older People and Implications for Health Policy and Practice","volume":"385","author":"Prince","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cger.2017.09.003","article-title":"Screening for Medication Appropriateness in Older Adults","volume":"34","author":"Zullo","year":"2018","journal-title":"Clin. Geriatr. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.144.5.612","article-title":"A Retrospective Analysis of Patients with Bullous Pemphigoid Treated with Methotrexate","volume":"144","author":"Kjellman","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ijd.14270","article-title":"Tetracycline, Nicotinamide, and Lesionally Administered Clobetasol as a Therapeutic Option to Prednisone in Patients with Bullous Pemphigoid: A Comparative, Retrospective Analysis of 106 Patients with Long-Term Follow-Up","volume":"58","author":"Kowalczyk","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bedoui, Y., Guillot, X., S\u00e9lambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M.C., Ralandison, S., and Gasque, P. (2019). Methotrexate an Old Drug with New Tricks. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205023"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2011.00839.x","article-title":"The Use of Methotrexate in Dermatology: A Review","volume":"53","author":"Shen","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/jid.1969.165","article-title":"The Etiology and Treatment of Pemphigus and Pemphigoid","volume":"53","author":"Lever","year":"1969","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archderm.1978.01640230013003","article-title":"Bullous Pemphigoid:Therapy in Patients with and without Diabetes Mellitus","volume":"114","author":"Downham","year":"1978","journal-title":"Arch. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(99)70156-8","article-title":"Low-Dose Oral Pulse Methotrexate as Monotherapy in Elderly Patients with Bullous Pemphigoid","volume":"40","author":"Heilborn","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002512-200825080-00001","article-title":"Role of Methotrexate in the Treatment of Bullous Pemphigoid in the Elderly","volume":"25","author":"Patton","year":"2008","journal-title":"Drugs Aging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0190-9622(94)70227-6","article-title":"Low-Dose Methotrexate Treatment in Elderly Patients with Bullous Pemphigoid","volume":"31","author":"Paul","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","article-title":"Combined Treatment with Low-Dose Methotrexate and Initial Short-Term Superpotent Topical Steroids in Bullous Pemphigoid: An Open, Multicentre, Retrospective Study","volume":"165","author":"Merlet","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.138.9.1255","article-title":"Treatment of Bullous Pemphigoid by Low-Dose Methotrexate Associated with Short-Term Potent Topical Steroids: An Open Prospective Study of 18 Cases","volume":"138","author":"Dereure","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/archderm.139.11.1506-b","article-title":"Methotrexate for Bullous Pemphigoid: Preliminary Study","volume":"139","author":"Bara","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/09546634.2012.660519","article-title":"Bullous Pemphigoid: A Case Series with Emphasis on Long-Term Remission off Therapy","volume":"24","author":"Kwatra","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/ejd.2019.3501","article-title":"Methotrexate Is Safe and Efficient as Long-Term Treatment for Bullous Pemphigoid","volume":"29","author":"Delaumenie","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of Current Data on the Use of Methotrexate in the Treatment of Pemphigus and Pemphigoid","volume":"161","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1111\/jdv.14957","article-title":"Changing Prevalence of Diabetes Mellitus in Bullous Pemphigoid: It Is the Dipeptidyl Peptidase-4 Inhibitors","volume":"32","author":"Gravani","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-Induced Bullous Pemphigoid in Diabetes Mellitus Patients Receiving Dipeptidyl Peptidase-IV Inhibitors plus Metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jdi.13676","article-title":"Association between Dipeptidyl Peptidase-4 Inhibitors and Increased Risk for Bullous Pemphigoid within 3 Months from First Use: A 5-Year Population-Based Cohort Study Using the Japanese National Database","volume":"13","author":"Kuwata","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jaad.2020.01.084","article-title":"Low-Dose Methotrexate Use and Safety for Older Patients with Bullous Pemphigoid and Impaired Renal Function: A Cohort Study","volume":"82","author":"Fisch","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/agm2.12045","article-title":"Factors Associated with Medication Adherence in Older Patients: A Systematic Review","volume":"1","author":"Smaje","year":"2018","journal-title":"Aging Med. Milt."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.2147\/CIA.S182881","article-title":"Factors Influencing Adherence to Treatment in Older Adults with Hypertension","volume":"13","author":"Uchmanowicz","year":"2018","journal-title":"Clin. Interv. Aging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/ggi.12616","article-title":"Systematic Review of the Barriers Affecting Medication Adherence in Older Adults","volume":"16","author":"Yap","year":"2016","journal-title":"Geriatr. Gerontol. Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:01Z","timestamp":1760138641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11113193"],"URL":"https:\/\/doi.org\/10.3390\/jcm11113193","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}